Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2012

Open Access 01-12-2012 | Brief Report

The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer

Authors: Mohammad R. Akbari, Wojciech Kluźniak, Rachelle Rodin, Song Li, Dominika Wokołorczyk, Robert Royer, Aniruddh Kashyap, Janusz Menkiszak, Jan Lubinski, Steven A. Narod, Cezary Cybulski

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Login to get access

Abstract

Recently, the HOXB13 gene has been shown to be a susceptibility gene for prostate cancer. HOXB13 is overexpressed in breast cancer tissues and HOXB13 expression in combination with low expression of IL17BR is predictive for a tamoxifen response in ER-positive breast cancers. Based on observations, we hypothesized that the HOXB13 p.Gly84Glu mutation might be associated with breast cancer risk. We genotyped this mutation in the germline DNA of 4,037 women with breast cancer (including 1,082 familial cases) and in 2,762 controls from Canada and Poland. Seven heterozygous carriers of the HOXB13 p.Gly84Glu mutation were found in the cases (0.17 %) compared to four carriers among the controls (0.14 %; OR = 1.2, 95 % CI = 0.34–4.1, p = 1.0). Only one of the seven carriers had a family history of breast cancer. This study does not support the hypothesis that women who carry the HOXB13 Gly84Glu mutation are at increased risk of breast cancer.
Literature
1.
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef
2.
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRef
3.
Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 9:665–676CrossRef
4.
Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241PubMedCrossRef
5.
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59PubMedCrossRef
6.
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167PubMedCrossRef
7.
Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD et al (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366(2):141–149PubMedCrossRef
8.
Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A et al (2012) Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 104(16):1260–1262PubMedCrossRef
9.
Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR (2012) Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev 21(8):1348–1353PubMedCrossRef
10.
11.
Nunes FD, de Almeida FC, Tucci R, de Sousa SC (2003) Homeobox genes: a molecular link between development and cancer. Pesqui Odontol Bras 17(1):94–98PubMedCrossRef
12.
Cantile M, Pettinato G, Procino A, Feliciello I, Cindolo L, Cillo C (2003) In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer 39(2):257–264PubMedCrossRef
13.
Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6):607–616PubMedCrossRef
14.
Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24(28):4611–4619PubMedCrossRef
15.
Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL et al (2007) HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 25(6):662–668PubMedCrossRef
16.
Alanee S, Couch F, Offit K (2012) Association of a HOXB13 variant with breast cancer. N Engl J Med 367(5):480–481PubMedCrossRef
17.
Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH (2004) HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 64:9185–9192PubMedCrossRef
Metadata
Title
The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer
Authors
Mohammad R. Akbari
Wojciech Kluźniak
Rachelle Rodin
Song Li
Dominika Wokołorczyk
Robert Royer
Aniruddh Kashyap
Janusz Menkiszak
Jan Lubinski
Steven A. Narod
Cezary Cybulski
Publication date
01-12-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2295-y

Other articles of this Issue 3/2012

Breast Cancer Research and Treatment 3/2012 Go to the issue

Epidemiology

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality

Letter to the Editor

Comment on prognostic and therapeutic implications of mTORC2 and rictor expression in human breast cancer

Clinical trial

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

Epidemiology

Time to diagnosis and breast cancer stage by race/ethnicity

Epidemiology

Pattern of follow-up care and early relapse detection in breast cancer patients

Preclinical Study

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits